Tags » Investing
This Supersedes April 22, 2019 News Release
Vancouver, British Columbia–(Newsfile Corp. – April 23, 2019) – NervGen Pharma Corp. (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has increased the amount of its non-brokered private placement announced on March 14, 2019 from $500,000 to $740,000. 1,217 more words
Motley Fool: Is This 100-Year-Old Engine Maker Facing a Crisis or Just a Slowdown?.